Business
Data from real-world clinical use of Feraccru
Data from real-world clinical use of Feraccru.
About this update from Shield Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 8305S Shield Therapeutics PLC 28 June 2018 \n\nShield Therapeutics plc\n(\"Shield\" or the \"Group\")\nShield reports recently presented supportive data from \nreal-world clinical use of Feraccru® (Ferric Maltol) \n \nLondon, UK, 28 June 2018: Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs, today reports on recent presentations of results from two studies of the use of Feraccru in clinical practice. The FRESH study (Feraccru® Real World Effectiveness Study in Hospital Practice) was presented at the British Society of Gastroenterology in Liverpool and data from a health economic study has been presented at the recent European Haematology Association meeting in Stockholm. Feraccru is a novel oral ferric iron therapy that is approved and marketed in Europe for the treatment of iron deficiency (ID).\n \nControlled clinical studies can overestimate the effectiveness of new medicines and under report tolerability issues due to the willingness of subjects to remain on study despite adverse events. This has been shown to be common for oral iron preparations, where real life data often demonstrates poorer compliance than seen in studies. \n \nThe FRESH study was conducted across seven UK hospitals and is the first published evaluation of the use of Feraccru in clinical practice; whilst researchers at the London North West University Healthcare NHS Trust reported on the potential health economic benefit of using Feraccru in patients who would otherwise have been considered for IV iron therapy.\n \nPreliminary results:\nThe FRESH study reported that, in inflammatory bowel disease (IBD) patients with recorded haemoglobin (Hb) measurements at 12 weeks, 62% had normalised Hb (≥12.0 g/dL for females and ≥13.0 g/dL for males). Dr Fraser Cummings, consultant gastroenterologist at Southampton General Hospital, commented \"Importantly, this result is comparable to that of the AEGIS phase III study (66% of patients with normalised Hb by 12 weeks) and supports the clinical effectiveness of Feraccru in real world clinical practice.\"\n \nDr Silvia Lovato, Honorary Senior Clinical Lecturer, London North West University Healthcare NHS Trust said, \"We audit...